R21疟疾疫苗季节性大规模接种在冈比亚与布基纳法索降低感染风险
Seasonal mass vaccination with R21 malaria vaccine effective in reducing malaria infection
The Lancet 发表一项开放标签集群随机对照试验,R21/Matrix-M 疫苗在雨季前对冈比亚30个村及布基纳法索24个村的人群接种三剂,在峰值流行期将感染几率分别降低70%和25%,临床疟疾病例分别下降47%和30%。研究者称这是首次用儿童使用的R21疫苗开展全社区疫苗接种,并指出该策略可增加疟疾控制工具选择。
原文明确给出集群随机试验设计与两国的保护率差异,读者可据传播强度评估该策略适用场景。
Vaccinating whole communities with the malaria vaccine R21 before the rainy season, alongside existing malaria control tools, can reduce the odds of infection by up to 70%, according to a new study published in The Lancet.
The study was conducted in The Gambia, where malaria is seasonal with low-to-moderate transmission, and in Burkina Faso, where transmission is intense. It found that seasonal mass vaccination with the R21/Matrix-M (R21) vaccine, given to entire communities ahead of the rainy season, significantly reduced the proportion of individuals infected with malaria at peak transmission in November in both countries. It also reduced the number of patients with clinical malaria by 47% in The Gambia and 30% in Burkina Faso.
This is the first study that vaccinated whole communities against malaria with a vaccine, R21, that is used in small children. Seasonal mass vaccination can become a vital additional tool to reduce the burden of malaria and help in progressing toward elimination efforts.
Testing vaccination across whole communities
Malaria continues to be life-threatening in many communities. Children under 5, pregnant women and people living with HIV or AIDS are at higher risk of severe infection. But global progress against malaria has stalled over the past decade, with cases and deaths well above the levels needed to reach elimination targets.
Umberto D'Alessandro, professor and principal investigator of the SERVAL study at MRC Unit The Gambia at London School of Hygiene & Tropical Medicine, said, "The study clearly shows that R21 can decrease malaria in older children, adolescents and adults, disproving previous assumptions that the vaccine would not be effective in these age groups. This is important as it can provide, besides an additional intervention against malaria, some insights on the mechanisms of immunity against malaria infection."
Of the 54 villages (30 in The Gambia and 24 in Burkina Faso), half received three monthly doses of R21 between May and August, ahead of the peak transmission season, with the other half serving as the control group. Standard malaria control interventions, including seasonal malaria chemoprevention, continued in both countries.
Protection varies with transmission intensity
Findings showed that the odds of malaria infection were reduced by 70% in The Gambia and by 25% in Burkina Faso. In The Gambia, the reduction in prevalence was seen across all age groups. In Burkina Faso, where transmission is intense and exposure is already high, the highest reduction rates were seen among children under 5, who are most at risk of malaria and its effects. However, some protective effect could also be seen in older age groups.
Halidou Tinto, professor and principal investigator of the SERVAL study at the Clinical Research Unit of Nanoro, Burkina Faso, said, "In Burkina, where children are intensely and repeatedly exposed to malaria each rainy season, we found that the protective effect of the vaccine was concentrated in the youngest children, those who bear the heaviest burden of the disease. Thus, even in a context of high transmission, seasonal mass vaccination combined with chemoprevention enabled a measurable reduction in infection. This is an encouraging outcome for communities in the Sahel region."
Wandifa Samateh, program manager for the National Malaria Control Programme at the Ministry of Health, The Gambia, said, "These results are an important signal for our national malaria control program. Mass vaccination, added onto the interventions we already deliver, could significantly lessen the burden of the disease on our communities. We look forward to working with our research partners to assess how this strategy could be integrated into our national malaria control and elimination plans."
The study demonstrated that the vaccine was safe and well tolerated in both countries, with mild, self-limiting adverse events reported, mostly mild headache and fever.
Publication details
Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial, The Lancet (2026). DOI: 10.1016/S0140-6736(26)01562-X
Journal information: The Lancet
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Seasonal mass vaccination with R21 malaria vaccine effective in reducing malaria infection (2026, November 19) retrieved 19 November 2026 from https://medicalxpress.com/news/2026-11-seasonal-mass-vaccination-r21-malaria.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com